← Eichor
Condition: Locally Advanced Or Metastatic Pancreatic Cancer Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Locally Advanced Or Metastatic Pancreatic Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
Phase 4 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT05035147The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
Phase 3 · 3 location(s) · Quercis Pharma AG · NCT06861088The KN510713 Study in Combination With mFOLFIRINOX
Phase 1/Phase 2 · 1 location(s) · New Cancer Cure-Bio Co.,Ltd. · NCT07114861A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Phase 1 · 10 location(s) · Dren Bio · NCT06999187Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07480928Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 · 18 location(s) · MOMA Therapeutics · NCT06545942A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Phase 2 · 85 location(s) · Daiichi Sankyo · NCT06172478A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
Phase 2 · 7 location(s) · Akeso · NCT05859750Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors
Phase 1 · 1 location(s) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · NCT07589205EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410676OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
EARLY_Phase 1 · 1 location(s) · OHSU Knight Cancer Institute · NCT07089940A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
Phase 1/Phase 2 · 14 location(s) · Astellas Pharma Global Development, Inc. · NCT07488676Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma
Phase 1/Phase 2 · 1 location(s) · Beijing Biotech · NCT07627711A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harbor
Phase 2 · 31 location(s) · Allist Pharmaceuticals, Inc. · NCT06008288Adebrelimab and Chidamide for Pancreatic Cancer
Phase 2 · 1 location(s) · Liu Xiufeng · NCT06584227A Single-center, Prospective, Two Cohort Study of Surufatinib Combined With AG or AG in the First-line Treatment of Loca
Phase 2 · 1 location(s) · Fudan University · NCT05969171Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
Phase 1/Phase 2 · 1 location(s) · BeyondBio Inc. · NCT03579836A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerabili
Phase 1/Phase 2 · 10 location(s) · ITM Oncologics GmbH · NCT05706129HRS-4642 Combination With Other Antitumor Therapies in Patients With Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Shanghai Hengrui Pharmaceutical Co., Ltd. · NCT07296341Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
Phase 2 · 22 location(s) · UNICANCER · NCT06333314A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal
Phase 1 · 46 location(s) · Astellas Pharma Global Development, Inc. · NCT05365581Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients With Panc
Phase 2 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06491472A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Canc
Phase 1 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT06500052Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or
Phase 2 · 1 location(s) · Centre Georges Francois Leclerc · NCT05988814A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 · 6 location(s) · Kivu Bioscience Inc. · NCT07229313A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positi
Phase 3 · 1 location(s) · Innovent Biologics (Suzhou) Co. Ltd. · NCT07066098XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.
Phase 1/Phase 2 · 1 location(s) · Evopoint Biosciences Inc. · NCT06792435NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06405490Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
Phase 2 · 1 location(s) · Fudan University · NCT06313970
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.